NCT03657810View on ClinicalTrials.gov

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

PHASE3CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

April 16, 2018

Study Completion Date

November 30, 2018

Conditions
PainNauseaVomiting
Interventions
DRUG

CL-108 5 mg

hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg

DRUG

Norco

hydrocodone 5 mg/APAP 325 mg

DRUG

Placebo

Placebo matching CL-108

Trial Locations (5)

21122

Chesapeake, Pasadena

78240

Endeavor Clinical Research, San Antonio

78705

Optimal Research, Austin

84124

Jean Brown Research, Salt Lake City

85023

Arizona Research Center, Phoenix

Sponsors
All Listed Sponsors
lead

Charleston Laboratories, Inc

INDUSTRY

NCT03657810 - A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV | Biotech Hunter | Biotech Hunter